KINASE INHIBITOR-1 OPTIONS

Nilotinib is at this time accredited by FDA as front-line therapy for Long-term stage CML and for patients who will be resistant or intolerant to imatinib.Tyrosine kinase inhibitors treat a wide range of cancers and lead to an Similarly big selection of side effects. For example, a person group of tyrosine kinase inhibitors targets cancers like non